Table 3.
Characteristics of patients with invasive fungal disease under primary antifungal prophylaxis with liposomal amphotericin B or posaconazole
| Patient | Age at diagnosis (years) | Diagnosis (ALL/AML) | IFD classification (per EORCT) | Pathogen | HSCT | Timing of IFD onset | Infection site | Time to event (days) | Death |
|---|---|---|---|---|---|---|---|---|---|
| L-AMB | |||||||||
| 1 | 14 | ALL | 1 | X | Yes | 1 | 2 | 135 | No |
| 2 | 10 | ALL | 2 | Aspergillus | No | 1 | 1 | 13 | No |
| 3 | 2 | ALL | 1 | X | No | 1 | 1 | 32 | No |
| 4 | 3 | ALL | 2 | Candida | No | 2 | 3 | 1308 | No |
| 5 | 15 | ALL | 2 | Aspergillus | No | 1 | 1 | 423 | No |
| 6 | 0.25 | ALL | 1 | X | Yes | 1 | 1 | 74 | No |
| 7 | 13 | ALL | 2 | Aspergillus | Yes | 3 | 2 | 1937 | No |
| 8 | 17 | AML | 2 | Aspergillus | No | 1 | 1 | 1048 | Yes |
| 9 | 10 | AML | 1 | X | Yes | 1 | 2 | 141 | No |
| 10 | 12 | AML | 3 | Aspergillus flavus | Yes | 3 | 1 | 1160 | No |
| Posacona-zole | |||||||||
| 11 | 3 | ALL | 2 | Aspergillus | Yes | 2 | 1 | 522 | No |
| 12 | 17 | ALL | 2 | Aspergillus | Yes | 3 | 1 | 220 | No |
| 13 | 0.25 | ALL | 3 | C. albicans | Yes | 1 | 2 | 90 | No |
| 14 | 9 | AML | 3 | Aspergillus | Yes | 3 | 1 | 231 | Yes |
Shown are diagnosis (ALL/AML), IFD classification based on EORCT criteria (1 = possible, 2 = probable, 3 = proven), identified pathogens, timing of IFD onset during treatment (1 = during chemotherapy (before HSCT), 2 = during relapse treatment (before HSCT), 3 = post-HSCT, infection site (1 = lung, 2 = liver, 3 = colon), and outcome. “X” indicates no specific pathogen identified
ALL acute lymphoblastic leukemia, AML acute myeloid leukemia, EORCT European Organization for Research and Treatment of Cancer, HSCT hematopoietic stem cell transplantation, IFD invasive fungal disease, L-AMB liposomal amphotericin B